# US 5,705,614 A · Methods of producing antigen forks

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,705,614 A
- Document ID: US5705614A
- Status: Granted
- Kind: A
- Application number: 08/396,595
- Filed: 1995-03-01
- Granted: 1998-01-06
- Earliest claimed: 1993-04-09
- Assignees: Chiron Corporation
- Inventors: David B. Ring
- Web page: https://patentgrep.com/patent/US5705614A

## CPC

- C07K 16/30: from tumour cells
- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a class of molecules called "antigen forks" that inhibit cell growth. These antigen forks possess separate binding elements for two different cell surface antigens and are believed to heterologously crosslink the antigens by binding to them. The two antigens recognized by an antigen fork differ in at least one cellular functional quality, but are simultaneously expressed on the surface of at least one cell type targeted for killing or growth inhibition. The present invention also relates to a method of assay to determine which antibodies may be useful in the preparation of antigen forks.

## Claims

### Claim 1

A method of producing antigen forks, said method comprising:
a. contacting a homogeneous culture of cells with a first antibody, said first antibody having an antigen binding site capable of recognizing and binding to a first antigen present on the surface of said cells under conditions allowing said first antibody to bind to said cells;
b. contacting said homogeneous culture of cells with a second antibody, said second antibody having an antigen binding site capable of recognizing and binding to a second antigen present on the surface of said cells under conditions allowing said second antibody to bind of said cells, said first and second antibodies having at least one common epitope;
c. contacting said first and second antibodies with a third antibody, said third antibody capable of recognizing and binding said at least one common epitope under conditions allowing said third antibody to bind to said first and second antibodies;
d. determining whether treatment of said cells according to steps (a) through (c) results in a decrease in the viability of said cells;
e. constructing said antigen fork using a molecule comprising said antigen binding site from said first antibody and a molecule comprising said antigen binding site from said second antibody when said treatment of said cells according to steps (a) through (c) results in a decrease in the viability of said cells.